Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
P/E ratio for Satsuma Pharmaceuticals, Inc. (STSA)
P/E ratio as of 2022: -0.42
According to Satsuma Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.42. At the end of 2021 the company had a P/E ratio of -2.56.
P/E ratio history for Satsuma Pharmaceuticals, Inc. from 2017 to 2022
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2022 | -0.42 |
| 2021 | -2.56 |
| 2020 | -1.68 |
| 2019 | -4.05 |
| 2018 | -9.07 |
| 2017 | -22.23 |